文章：

非霍奇金淋巴瘤的双特异性和三特异性抗体：当前数据与展望

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

原文发布日期：2024-01-25

DOI: 10.1038/s41408-024-00989-w

类型: Review Article

开放获取: 是

英文摘要：

Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.
 

摘要翻译： 

双特异性抗体是一类新型靶向疗法，正在彻底改变B细胞非霍奇金淋巴瘤的治疗格局。在复发/难治性患者中，挽救性化疗联合自体干细胞移植仅能治愈50%的患者，而另一半患者预后极差，中位总生存期不足12个月。这一未满足的临床需求凸显了双特异性抗体与CAR-T细胞疗法等创新治疗方案的重要性。本篇综述将从临床前研发到难治性及一线治疗的临床数据，深入探讨双特异性抗体在B细胞非霍奇金淋巴瘤中的应用，并展望其未来发展方向。

原文链接：

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives